Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Point of Care Molecular Diagnostics Companies

ID: MRFR/HC/9964-HCR
200 Pages
Rahul Gotadki
Last Updated: February 16, 2025
Driving rapid and accurate diagnostics, Point of Care Molecular Diagnostics companies focus on developing portable testing solutions. Their innovative technologies enable on-the-spot molecular analysis, providing timely and reliable results for infectious diseases and genetic conditions, ultimately improving patient outcomes through targeted interventions.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Point of Care Molecular Diagnostics Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.28%
2024 Market Size$ 6.25 Billion
2025 Market Size$ 6.76 Billion
2035 Market Size$ 14.99 Billion
Key Players
Companies such as Abbott Laboratories
Roche Diagnostics
Thermo Fisher Scientific
Cepheid
Hologic
Inc.
Trends
  • Technological Advancements
  • Shift Towards Personalized Medicine
  • Integration with Telehealth Services
Opportunities
  • Supportive Regulatory Environment
  • Rising Demand for Rapid Diagnostics
  • Growing Focus on Preventive Healthcare
Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Point of Care Molecular Diagnostics Market

Point-of-Care Molecular Diagnostics Key Companies
 
Latest Point-of-Care Molecular Diagnostics Companies Update:

QIAGEN N.V. expands its reach in Japan with the launch of its QIAstat-Dx system and a respiratory panel for syndromic testing. This new offering provides rapid and accurate diagnosis of influenza A/B, RSV, and other respiratory pathogens, enhancing timely interventions in a critical region.

Biocartis NV receives CE marking for its Rapid Idylla GeneFusion Panel, enabling faster treatment decisions in lung cancer patients. This innovative test identifies specific gene fusions associated with targeted therapies, allowing for personalized treatment plans.

Roche Diagnostics unveils its Cobas Pulse System in certain countries with CE Mark acceptance. This next-generation platform offers integrated solutions for professional blood glucose management, catering to the growing demand for point-of-care diabetes monitoring.

List of Point-of-Care Molecular Diagnostics Key companies in the market
  • Abbott Laboratories, Inc. (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • QIAGEN N.V. (Germany)
  • Becton, Dickinson and Company (US)
  • Cepheid (US)
  • altona Diagnostics GmbH (Germany)
  • Siemens Healthineers AG (Germany)
  • Thermo Fisher Scientific, Inc. (US)
  • ELITechGroup (France)
  • Trinity Biotech plc (Ireland)

Related Reports

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035